The Patent Finder

Seagen Inc.

136 patents currently held · Updated Nov 15, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Seattle Genetics, Inc. (to 2020)

41
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Dec 6 to 25, 2026 · next Dec 6
  • 4 fees due Jan 7 to 16, 2027 · next Jan 7
  • 2 fees due Feb 22 to 27, 2027 · next Feb 22
  • 3 fees due Mar 1 to 26, 2027 · next Mar 1
  • 5 fees due Apr 8 to 29, 2027 · next Apr 8
  • 5 fees due May 5 to 28, 2027 · next May 5
  • 2 fees due Jun 15 to 19, 2027 · next Jun 15
  • 2 fees due Jul 2 to 26, 2027 · next Jul 2
  • 2 fees due Aug 6 to 18, 2027 · next Aug 6
  • 4 fees due Sep 1 to 26, 2027 · next Sep 1
  • 2 fees due Oct 2 to 19, 2027 · next Oct 2

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,345,785Treatment of renal cell carcinoma with anti-CD70 antibody-drug conjugates
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,428,585Humanized anti-CD70 binding agents and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,051,372Anti-CD70 antibody and its use for the treatment of cancer and immune disorders
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,994,135Monomethylvaline Compounds Capable of Conjugation to Ligands
In force
 · High confidence
In forceHigh confidence
US 7,964,566Monomethylvaline Compounds Capable of Conjugation to Ligands
In force
 · High confidence
In forceHigh confidence
US 7,964,567Monomethylvaline Compounds Capable of Conjugation to Ligands
In force
 · High confidence
In forceHigh confidence
US 8,512,707Methods of treating drug-resistant cancers
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,750,116Antibody drug conjugate metabolites
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,695,716Methods of treating neoplastic, autoimmune and inflammatory diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US RE45,272β-glucuronide-linker drug conjugates
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 136 patents shown.
Pro members see all 136.
Pro members: see all 136 patents
Also on record, not counted in the 136: 3 patents in force now held by others · 24 lapsed for an unpaid fee · 38 ended at full term · 5 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

35 pending · 34 abandoned · 70 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited